Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Change in Account Payables (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Change in Account Payables data on record, last reported at -$5.5 million in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 344.68% year-over-year to -$5.5 million; the TTM value through Dec 2025 reached -$7.3 million, down 1116.18%, while the annual FY2025 figure was -$7.3 million, 1116.18% down from the prior year.
  • Change in Account Payables reached -$5.5 million in Q4 2025 per MRVI's latest filing, down from -$2.9 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.6 million in Q2 2024 and bottomed at -$5.5 million in Q4 2025.
  • Average Change in Account Payables over 5 years is -$112100.0, with a median of $712000.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: surged 12770.59% in 2021, then crashed 1466.81% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at -$867000.0 in 2021, then crashed by 300.0% to -$3.5 million in 2022, then soared by 147.84% to $1.7 million in 2023, then soared by 35.86% to $2.3 million in 2024, then plummeted by 344.68% to -$5.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$5.5 million in Q4 2025, -$2.9 million in Q3 2025, and $1.8 million in Q2 2025.